Wendell Lim, a leader in synthetic biology, chairs the Department of Cellular and Molecular Pharmacology at UCSF. He co-founded Cell Design Labs in 2015 with Brian Atwood of Versant Ventures. Cell Design Labs, developing two technologies in the CAR-T cell cancer immunotherapy space, made such rapid progress that it was acquired two years later by Gilead for $567 million. Join us to hear about Wendell's experience launching Cell Design Labs and the lessons he learned commercializing a cutting-edge technology.
Where and When
Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Noon to 1:00 PM, Thursday, December 6
About the Speaker
Wendell Lim is the Byers Distinguished Professor and Chair of the Department of Cellular and Molecular Pharmacology at the University of California San Francisco, and an Investigator of the Howard Hughes Medical Institute. He received his A.B. in Chemistry, summa cum laude, from Harvard College, his Ph.D. in Biochemistry and Biophysics at the Massachusetts Institute of Technology and completed his postdoctoral training at Yale University. His research focuses on the design principles of molecular circuits that govern cell decision-making and responses. His lab has made contributions in understanding the molecular machinery of cell signaling and how molecular modules have been used in evolution to build novel new behaviors. Most recently he has been a pioneer in the emerging field of synthetic biology, exploring how these design principles can be harnessed to engineer cells with customized therapeutic response programs. He is an author of the textbook, Cell Signaling (Garland Science 2014) and was the founder of the cell therapy biotech startup, Cell Design Labs, which was acquired by Gilead Biosciences in 2017.